NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term
_256_384.png)
This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad
Subscribe To Our Newsletter & Stay Updated
